Treatment of Androgen Dependent Prostate Cancer with Drugs in Combination

Abstract

The battle against prostate cancer, a leading cause of cancer-related deaths among men, demands innovative and more effective treatment strategies. Current therapies often fall short, particularly in advanced stages, necessitating a breakthrough to improve patient outcomes.

Researchers at FAU have developed a pioneering combination therapy, leveraging the synergistic potential of KBU2046 and calcitriol. This novel approach specifically targets androgen-dependent prostate cancer cells, showcasing a significant leap forward in treatment efficacy. By meticulously inhibiting cancer cell motility and proliferation, this combination therapy not only seeks to eliminate the cancerous cells but also aims to impede the progression and recurrence of the disease. This dual-action strategy represents a significant advancement over existing treatments, offering a potent solution that addresses the urgent need for more effective and safer prostate cancer therapies.

FAU seeks to advance this innovation into the marketplace through licensing or development partnerships.

Benefit

Market Application